PT-141 (Bremelanotide) Review: Best Source, Dosing & What to Expect (2026)

Quick Take: offers PT-141 at $45 for 10mg — among the most competitive pricing for a tier-1, COA-verified source. PT-141 (Bremelanotide) is the only peptide with clinical data specifically targeting sexual dysfunction through central nervous system mechanisms. For researchers studying melanocortin pathways and sexual function, this is the compound and pricing makes it accessible.

PT-141 (Bremelanotide) occupies a unique position in the research peptide space: it's the only peptide with FDA approval specifically for sexual dysfunction (as Vyleesi for FSIAD), and the only compound that addresses libido through central nervous system pathways rather than peripheral vascular mechanisms like PDE5 inhibitors.

This makes it genuinely interesting research material — the mechanism is distinct from anything else in the peptide catalog, and the human clinical data backing it is unusually robust for a research compound. At $45 for 10mg, Ascension Peptides' offering is worth examining in detail.

Ascension's PT-141 Offering

• PT-141 10mg — $45
• Lyophilized powder, batch-specific COA (≥98% HPLC purity)
• Mass spectrometry identity verification
• US domestic shipping, 2–4 business days

How PT-141 Works: The Mechanism That Makes It Different

PT-141 is a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (α-MSH). It activates melanocortin receptors — specifically MC3R and MC4R — in the hypothalamus and limbic system. These brain regions are central to motivation, reward, and sexual arousal signaling.

The key distinction from PDE5 inhibitors (sildenafil, tadalafil): PT-141 doesn't work on blood flow. It works on the brain's desire circuitry. PDE5 inhibitors create the physical capacity for sexual response; PT-141 influences the psychological and motivational signal itself. This makes it relevant to research on disorders where physical function is intact but desire is impaired — a clinically distinct problem.

Specific mechanisms documented in research:

• MC4R activation in the hypothalamus — triggers downstream dopaminergic activity associated with sexual motivation and arousal
• Oxytocin release modulation — influences bonding and pleasure neurotransmitter systems alongside arousal
• Central rather than peripheral action — effects are CNS-mediated, not dependent on local vascular response
• Non-hormonal mechanism — does not alter testosterone, estrogen, or other sex hormones in research settings

Clinical Research Data

PT-141's research profile is unusually strong for a peptide available as a research compound. Phase II and Phase III trials established:

• Significant improvements in sexual desire and arousal in women with hypoactive sexual desire disorder (HSDD) — the basis for FDA approval of Vyleesi
• Dose-dependent improvements in erectile function scores in men with erectile dysfunction — including subjects who were non-responsive to PDE5 inhibitors
• Rapid onset of action (30–60 minutes post-administration)
• Duration of effects: 6–12 hours in clinical observations

The fact that PT-141 showed efficacy in men who didn't respond to PDE5 inhibitors is clinically significant — it suggests a distinct patient population and mechanism that warrants independent research attention.

Research Dosing

• Typical dose: 1–2 mg subcutaneous injection
• Onset: 30–60 minutes post-injection
• Duration: 6–12 hours
• Frequency: Not for daily use — receptor desensitization occurs with frequent dosing; 1–2× per week is the standard research interval
• Reconstitution: Bacteriostatic water; 1mL per vial for 10mg/mL concentration; 0.1mL = 1mg dose

At 10mg per vial and 1–2mg per research session, Ascension's 10mg vial provides 5–10 research administrations. At $45 that's $4.50–$9 per dose — competitive pricing for documented, COA-verified product.

Side Effects Documented in Research

• Nausea — most common (reported in ~40% of subjects in clinical trials); typically mild and transient; dose-dependent; usually resolves within 2 hours
• Flushing — facial and upper body warmth; common in first 1–2 administrations
• Spontaneous erections — in men, within 1–2 hours post-injection regardless of stimulation; dose-dependent
• Transient blood pressure changes — mild and brief; contraindicated with cardiovascular compromise in clinical settings
• Hyperpigmentation — with very frequent use; rare at research dosing intervals

The nausea is the primary tolerability issue in research. It's manageable at 1mg doses and often diminishes with repeated administrations as subjects acclimate. Starting at 0.5–1mg in naive research subjects reduces this risk.

Pricing vs. Competitors

Ascension's PT-141 is priced at the most competitive end of the tier-1 vendor range. At $4.50/mg with third-party COA documentation, it's among the best value available from a verifiable source.

PT-141 vs. Other Sexual Health Peptides

The only other peptide with meaningful data in sexual health research is Kisspeptin, which operates via GnRH stimulation — a hormonal rather than direct CNS desire mechanism. The two compounds address completely different aspects of sexual function and are not interchangeable in research design. stocks Kisspeptin at $58/10mg alongside PT-141, making both available for comparative research.

FAQ

Is PT-141 the same as Melanotan II?

Related but distinct. Melanotan II is an older analog of α-MSH with both tanning and sexual effects via MC1R and MC4R activation. PT-141 (Bremelanotide) was developed specifically to target the sexual function mechanism without the tanning side effects, by removing the α-MSH segment responsible for MC1R activity. PT-141 is the more specific compound for sexual health research; Melanotan II has broader melanocortin receptor activity including the skin pigmentation pathway.

Can PT-141 be used intranasally?

Early research used intranasal delivery. Subcutaneous injection has become the standard in later research due to more consistent bioavailability. The FDA-approved Vyleesi formulation uses subcutaneous auto-injector delivery.

Does PT-141 work differently in men vs. women?

The central mechanism (MC3R/MC4R) is similar in both sexes. FDA approval for Vyleesi was granted specifically for premenopausal women with HSDD. Research in men shows effects on erectile function via CNS arousal pathways — distinct from PDE5 inhibitor mechanisms but clinically complementary to them.

→ Source PT-141 from Ascension: Ascension Peptides

This content is for informational and educational purposes only. PT-141/Bremelanotide is available for research purposes only. It is FDA-approved as Vyleesi for HSDD under prescription only. PeptideDeck may earn a commission from purchases through affiliate links at no additional cost to you.